Ceva Sante Animale

Shionogi Company Limited

Nippon Zeon Company, Ltd.

Zeon Corporation

Ceva Santa Animale

Taisho Pharmaceutical Co., Ltd.

Shuji Saito

Ayumi Fujisawa

Sakiko Saeki

Mayumi Kubomura

Yoshikazu Iritani

Shigemi Aoyama

Noboru Yanagida

Kouichi Kamogawa

Kazumi Kodama

Takanori Sato

Takashi Okuda

Katsuo Hatayama

Kensei Yoshikawa

Yoshinari Tsuzaki

Yohichi Shimazaki

Mariko Kashiwa

Kristi M Moore

Setsuko Ohkawa

The present invention relates to a recombinant avian herpes virus, which comprises at least two recombinant nucleotide sequences, each recombinant nucleotide sequence encoding a distinct antigenic peptide, wherein the at least two recombinant nucleotide sequences are inserted into distinct non-coding regions of the viral genome chosen among the region located between UL44 and UL45, the region located between UL45 and UL46, the region located between US10 and SORF3, and the region located between SORF3 and US2.

Multivalent recombinant avian herpes viruses and vaccines for immunizing avian species

The present invention relates to a recombinantherpes virus, which comprises at least two recombinant nucleotide sequences, each recombinant nucleotide sequence encoding a distinct antigenic peptide, wherein the at least two recombinant nucleotide sequences are inserted into distinct non-coding regions of the viral genome chosen among the region located between UL44 and UL45, the region located between UL45 and UL46, the region located between US10 and SORF3, and the region located between SORF3 and US2.

A polyvalent vaccine for chicken coccidium-herpesvirus infections comprising as an active ingredient a recombinant herpesvirus comprising a gene encoding SEQ ID NO: 5 which is a microneme protein of a chicken coccidium protozoa or a gene in which part thereof has been substituted, deleted, or added. By administering said polyvalent vaccine into the egg, subcutaneously or intramuscularly, coccidium infections and herpesvirus infections can be prevented.

Recombinant herpesvirus and polyvalent vaccine

There is provided a DNA molecule derived from a prokaryotic cell in which at least one of the DNA regions encoding NXB (N is asparagine, X is any amino acid other than proline, and B is serine or threonine) has been modified so that no N-glycosylation occurs during the expression in a eukaryotic cell, and since the DNA molecule has been modified at the N-glycosylation site, it produces a non-N-glycosylated protein, which thereby exhibits a high immunogenicity when, for example, it is allowed to produce, in a eukaryotic cell, an antigen protein derived from a prokaryotic cell.

Modified DNA molecule, recombinant containing the same, and uses thereof

Antigen proteins of Mycoplasma gallisepticum, genes encoding the antigen protein, recombinant vectors integrated with the gene and hosts transformed with the vector are provided. Diagnostics and vaccine using the antigen protein produced by such hosts are effective for poultry, especially chicken infected with Mycoplasma gallisepticum. Vaccination can maintain poultry free of Mycoplasma gallisepticum infection.

Poultry mycoplasma antigens and recombinant vectors containing the gene

Poultry Mycoplasma antigens and recombinant vectors containing the gene

Poultry mycoplasma antigen, gene thereof and recombinant vectors

Growing community of inventors

Kanagawa, Japan

Shuji Saito